New interim data from ongoing Phase 2b X-TOLE open-label extension demonstrates improvement in overall quality-of-life (QoL) when compared to baseline
Clinically important improvements seen for all patients across important subscales of Seizure Worry, Social Functioning and Medication Effects and for seizure free patients across all QoL subscales
Oral presentations showcase Phase 3 clinical trials in focal onset seizures and primary generalized tonic-clonic seizures
https://finance.yahoo.com/news/xenon-pharmaceuticals-showcases-xen1101-epilepsy-123000931.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.